Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations

被引:58
作者
Boettcher, Sebastian [1 ]
Ritgen, Matthias [1 ]
Buske, Sebastian [1 ]
Gesk, Stefan [2 ]
Klapper, Wolfram [3 ,4 ]
Hoster, Eva [5 ]
Hiddemann, Wolfgang [5 ]
Unterhalt, Michael [5 ]
Dreyling, Martin [5 ]
Siebert, Reiner [2 ]
Kneba, Michael [1 ]
Pott, Christiane [1 ]
机构
[1] Univ Schleswig Holstein, Dept Med 2, Kiel, Germany
[2] Univ Schleswig Holstein, Inst Human Genet, Kiel, Germany
[3] Univ Schleswig Holstein, Dept Haematopathol, Kiel, Germany
[4] Univ Schleswig Holstein, Lymph Node Registry Kiel, Kiel, Germany
[5] Univ Munich, Hosp Grosshadern, Dept Internal Med 3, Munich, Germany
关键词
mantle cell lymphoma; flow cytometry; PCR; staging; minimal residual disease;
D O I
10.3324/haematol.11267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The increasing application of multi-color flow cytometry assays for staging and follow-up in mantle cell lymphoma necessitates that the specificity and sensitivity of this technique are evaluated. Data from prospective clinical trials comparing the clinical applicability of flow cytometry to routine diagnostic methods and to polymerase chain reaction are currently lacking. Design and Methods We applied a standardized four-color flow cytometry assay to 281 prospectively collected peripheral blood and bone marrow samples from 98 patients with mantle cell lymphoma participating in a multi-center clinical trial and compared the results to those obtained with conventional clinical staging and consensus primer IGH-polymerase chain reaction. Results The maximum sensitivity of flow cytometry using light chain restriction in CD19'CD5' sub-populations was 8.0x10(-4) while flow cytometry that relied on immunophenotypic aberrations was less sensitive (2.4x10(-3)). Mantle cell lymphoma cells were detected in 87.3% of 110 pre-treatment samples from 84 patients by flow cytometry and in 94.5% by polymerase chain reaction. Eight out of 84 patients (9.5%) diagnosed clinically as having stage II or III disease showed peripheral blood or bone marrow involvement according to flow cytometry, thus documenting more advanced disease. At follow-up residual lymphoma cells were detected by flow cytometry and concordantly by polymerase chain reaction in 10/171 samples (5.8%); however, 31 follow-up samples (18.1%) were positive for minimal residual disease according only to polymerase chain reaction analysis. Conclusions The sensitivity of four-color flow cytometry is comparable to that of IGH-polymerase chain reaction at initial staging but is less sensitive at follow-up after immuno-chemotherapy. Both techniques are highly valuable methods for accurate initial staging.
引用
收藏
页码:551 / 559
页数:9
相关论文
共 51 条
  • [1] Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
    Andersen, NS
    Donovan, JW
    Borus, JS
    Poor, CM
    Neuberg, D
    Aster, JC
    Nadler, LM
    Freedman, AS
    Gribben, JG
    [J]. BLOOD, 1997, 90 (10) : 4212 - 4221
  • [2] Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma
    Andersen, NS
    Donovan, JW
    Zuckerman, A
    Pedersen, L
    Geisler, C
    Gribben, JG
    [J]. EXPERIMENTAL HEMATOLOGY, 2002, 30 (07) : 703 - 710
  • [3] A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors
    Andersen, NS
    Jensen, MK
    Brown, PD
    Geisler, CH
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) : 401 - 408
  • [4] Mantle cell lymphoma: A clinicopathologic study of 80 cases
    Argatoff, LH
    Connors, JM
    Klasa, RJ
    Horsman, DE
    Gascoyne, RD
    [J]. BLOOD, 1997, 89 (06) : 2067 - 2078
  • [5] Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study
    Borowitz, MJ
    Pullen, DJ
    Shuster, JJ
    Viswanatha, D
    Montgomery, K
    Willman, CL
    Camitta, B
    [J]. LEUKEMIA, 2003, 17 (08) : 1566 - 1572
  • [6] Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO
  • [7] 2-Z
  • [8] Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation
    Böttcher, S
    Ritgen, M
    Pott, C
    Brüggemann, M
    Raff, T
    Stilgenbauer, S
    Döhner, H
    Dreger, P
    Kneba, M
    [J]. LEUKEMIA, 2004, 18 (10) : 1637 - 1645
  • [9] Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma:: a prospective, multicenter phase II study
    Brugger, W
    Hirsch, J
    Grünebach, F
    Repp, R
    Brossart, P
    Vogel, W
    Kopp, HG
    Manz, MG
    Bitzer, M
    Schlimok, G
    Kaufmann, M
    Ganser, A
    Fehnle, K
    Gramatzki, M
    Kanzl, L
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (11) : 1691 - 1698
  • [10] Campana D, 1999, CYTOMETRY, V38, P139, DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO